Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

Gilead Sciences Inc., a prominent player in the biotechnology industry with a "GOOD" Financial Health Score according to InvestingPro, reported its first-quarter 2025 earnings, surpassing Wall ...

“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an effective ...

“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Speaking of Sanofi, Nurix is working with this big pharma to develop a STAT6 protein degrader to target TH2-mediated inflammatory disorders, such as Asthma, Atopic Dermatitis, and Allergies.

“GS-6791/NX-0479 is one drug candidate emerging from Nurix’s growing pipeline of degrader-based medicines designed to treat inflammation and autoimmune diseases, including our STAT6 degrader ...

Marfan syndrome (MFS) is a heritable connective tissue disorder caused by mutations in the Fibrillin‐1 gene, which encodes the extracellular matrix protein fibrillin‐1. Patients with MFS are ...

The SNPs rs17563 in BMP4 and rs1533767 in WNT11 were associated with facial proportion variations. Understanding the genetic basis underlying the normal-range variation of the human face has important ...

and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.